Swallowing A Bitter PillJane H. Cutaia
The high-flying pharmaceutical industry may get its wings clipped this year. U.S. drug companies still lead the world in research and development and rule its largest drug market. But they'll feel pressure on profits, as several major drugs lose patent protection. Prices could get pinched, too, as President-elect Clinton starts his drive against soaring health-care costs. Analysts figure the industry's aftertax margins could drop to 13%--one percentage point below last year's level and down six points from 1991--even as sales rise 10%, to about $82.5 billion.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Greenwich Mansion Listings Pulled to Wait for a Better Day
- U.S. Stocks Climb With Treasuries as Dollar Slides: Markets Wrap
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis